Detection of early lung cancer using low dose Photofrin II.
Fluorescence imaging using hematoporphyrin derivative (HpD) or Photofrin II as a tumor marker has been used for localization of early bronchogenic carcinoma. Wider clinical application of HpD or Photofrin II as a cancer imaging agent has been hampered by the potentially serious and prolonged skin photosensitivity. Using a sensitive fluorescence bronchoscope system with a ratio fluorometer probe, carcinoma in situ was detected in four patients with low dose Photofrin II (0.25 mg/kg) with no apparent skin phototoxicity to 30 J/cm2 visible light on skin photosensitivity test.
Lam
S
S
Cancer Control Agency of British Columbia, Vancouver, Canada.
Palcic
B
B
McLean
D
D
Hung
J
J
Korbelik
M
M
Profio
A E
AE
D000368:Aged; D001999:Bronchoscopy / Q000379:methods; D002278:Carcinoma in Situ / Q000175:diagnosis*; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis*; D017323:Dihematoporphyrin Ether; D005336:Fiber Optic Technology / Q000295:instrumentation; D005453:Fluorescence; D006415:Hematoporphyrins / Q000008:administration & dosage; D006801:Humans; D007834:Lasers; D008175:Lung Neoplasms / Q000175:diagnosis*; D008297:Male; D008875:Middle Aged; D010787:Photosensitivity Disorders / Q000175:diagnosis; D012882:Skin Tests
D006415:Hematoporphyrins; D017323:Dihematoporphyrin Ether